OverviewSuggest Edit
The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
| Type | Private | |
| Founded | 2011 | |
| HQ | London, GB | Map |
| Website | synthace.com |
Latest Updates
| Employees (est.) (Jun 2019) | 63 | (+9%) |
| Revenue (FY, 2013) | £581 |
Key People/Management at Synthace
Tim Fell
CEO
Christopher Grant Ward
Co-Founder
Markus Gershater
CSO
Sean Ward
Founder and CTO
Synthace Office Locations
Synthace has an office in London
London, GB (HQ)
2 Royal College St
Synthace Financials and Metrics
Summary Metrics
Founding Date | 2011 |
Synthace total Funding | $41.8 m |
Synthace latest funding size | $25.60 m |
Time since last funding | 6 months ago |
Synthace investors | Horizons Ventures, Amadeus Capital Partners, Sofinnova Partners, Rainbow Seed Fund, David Lucas, John Anthony Knight, Keith Willey, Michail Eleftheriou, Sami Mikati, Sharaf Yamani, SOSV, White Cloud Capital, Eleven Two Capital, Bioeconomy Capital, Luminous Ventures, Patrick Zhang |
Synthace's latest funding round in December 2018 was reported to be $25.6 m. In total, Synthace has raised $41.8 m
Synthace Revenue
Synthace's revenue was reported to be £581 in FY, 2013
| GBP | |
|---|---|
Revenue (FY, 2013) | 581.0 |
Net income (FY, 2013) | (361.6k) |
EBITDA (FY, 2013) | (356.8k) |
EBIT (FY, 2013) | (361.6k) |
Cash (31-May-2018) | 4.9m |
| GBP | FY, 2012 | FY, 2013 |
|---|---|---|
Revenue | 581.0 | |
Operating expense total | 362.2k | |
EBITDA | (356.8k) | |
EBITDA margin, % | (61413%) |
| GBP | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|
Cash | 351.4k | 103.4k | 321.7k | 1.5m | 245.0k | 224.3k | 4.9m |
Accounts Receivable | 240.0 | 159.9k | 73.2k | 9.6k | 46.6k | 107.7k | |
Current Assets | 358.1k | 150.1k | 481.6k | 1.6m | 646.8k | 883.2k | 5.8m |
PP&E | 1.6k | 14.8k | 298.8k | 200.5k | 265.6k | 186.8k | 235.7k |
| GBP | FY, 2012 | FY, 2013 |
|---|---|---|
Net Income | (43.1k) | (361.6k) |
| GBP | Y, 2018 |
|---|---|
Financial Leverage | 1.2 x |
Synthace Online and Social Media Presence
1.06k Twitter followers
Synthace has 1.06k Twitter Followers. The number of followers has increased 2.4% month over month and increased 14.8% quarter over quarter
Twitter Engagement Stats for @synthace
475
Tweets
108
Following
1.1k
Followers
8
Tweets last 30 days
4.9
Avg. likes per Tweet
100%
Tweets with engagement
Synthace News and Updates
December 12, 2018
Synthace raises $25.6 million to automate bio labs with software
Synthace, a U.K. startup developing an operating system to automate lab work, announced that it has raised $25.6 million in a Series B round.
September 19, 2017
Synthace reels in $9.6 mln Series A
London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.
Synthace Blogs
May 06, 2019
The cell and gene therapy market: why it matters
In the last four years there has been a noticeable push from investors,
companies and regulators to bring ever more complicated products, like the
CAR-T (Chimeric Antigen Receptor – T cell) therapies, to market. In this
blog post we focus on how the market has evolved and what the global ATMP
ec…
March 14, 2019
Synthace Chief Science Officer to Speak at BioProcess International US West
Synthace Senior Executive to address: Closing the loop in bioprocessing
with connected lab automation and data integration
March 11, 2019
Why Synthace is collaborating with Microsoft Research to change the way research on programming biological systems is conducted
By collaborating with Microsoft Research, Synthace hopes that we can employ
the expertise Microsoft brings in machine learning, cloud infrastructure
and network driven systems biology to accelerate the production of new
biological materials and therapeutics.
February 26, 2019
Closing the Loop in Big Pharma: Perspectives from the Top and Bottom
Back in the early autumn of 2018, we attended 2 events in short succession
where the topic of digital transformation in pharma loomed large. Here we
compare and contrast these two events, in which we find a commonality
between the C-suite and end user on the benefits of digital tools such as
aut…
February 10, 2019
An introduction to Real World Data: An Interview with Dr Susan Shiff
In this interview we sit down with Dr Susan Shiff MBA to discuss how data
is being obtained, analysed and used from across the healthcare system to
extract insights that deliver meaningful patient outcomes.
January 28, 2019
How lab automation can deliver a strong return on investment for biotech and pharma companies
Given the importance of measuring a return on investment (ROI) to the
continued usage of new software, here are several ways we’ve found that
automation delivers a strong ROI to researchers across a variety of
biological functions.
Synthace Frequently Asked Questions
When was Synthace founded?
Synthace was founded in 2011.
Who are Synthace key executives?
Synthace's key executives are Tim Fell, Christopher Grant Ward and Markus Gershater.
How many employees does Synthace have?
Synthace has 63 employees.
What is Synthace revenue?
Latest Synthace annual revenue is £581 .
What is Synthace revenue per employee?
Latest Synthace revenue per employee is £9 .
Who are Synthace competitors?
Competitors of Synthace include International Stem Cell Corporation, ProNAi Therapeutics and DBV Technologies.
Where is Synthace headquarters?
Synthace headquarters is located at 2 Royal College St, London.
Where are Synthace offices?
Synthace has an office in London.
How many offices does Synthace have?
Synthace has 1 office.